ALXN News and Press, Alexion Pharmaceuticals Inc. From 10/08/19

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019. Following the release of the financial results, Alexion management will conduct a c...

Omeros Corporation (OMER) is commercial stage pharmaceutical company with one marketed drug - Omidria, one late-stage, and several early-stage drug candidates. Omidria is used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing ...

Fortress Biotech ( FBIO ) has made significant progress since my 11/24/2018 article on the Fortress Biotech Inc. 9.375% Cum Conv Perp Red Pfd Registered Shs Series ( FBIOP ). Although FBIOP remains a speculative issue, it has appreciated in price from $17.58 to $20.00 since my last artic...

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Outperform rating and $146 (45% upside) price target at William Blair. More news on: Alexion Pharmaceuticals, Inc., Change Healthcare Inc., Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Converting a covered call trade to a collar trade can help maintain opportunity while locking in some unrealized profits, explains Alan Ellman . When we sell an in-the-money or at-the-money strike and share price moves up substantially, we have an unrealized maximum return. While we can sim...

- Aradhana Sarin, M.D., to become CFO after filing of Q3 2019 results - - Paul Clancy to step down as CFO and serve as senior advisor through mid-2020 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans for the transition of Executive Vice President and Chief Fin...

ANI Pharmaceuticals (NASDAQ: ANIP ) initiated with Buy rating and $76 (9% upside) price target at Guggenheim. More news on: ANI Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

With product candidates acquired from AstraZeneca ( AZN ) and MedImmune, Viela Bio ( VIE ) is clinical-stage biotechnology to be followed carefully. Besides, at Phase 3 of development, the company could deliver positive results in 2020, which may make the share price run. After the IPO, we exp...

Alexion Pharmaceuticals (NASDAQ: ALXN ) and BridgeBio Pharma's (NASDAQ: BBIO ) subsidiary Eidos Therapeutics (NASDAQ: EIDX ) have announced an agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan. More news on: Alexion Pharmaceuticals, I...

- Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 - - Agreement expands Alexion’...